Introduction {#s1}
============

Red yeast rice (RYR) is a traditional Chinese medicine and food supplement popular in East Asian countries such as China, Japan, Korea, and Thailand ([@B125]). It is produced by the fermentation of cooked rice kernels with a Monascaceae mold, *Monascus purpureus*, which turns rice into reddish purple kernels due to its pigmentation capability ([@B75]). As part of the Asian diet, RYR is used as a food additive to enhance the color of meat, fish, and soybean products. It is also recognized as a folk medicine for rejuvenating the body, promoting blood circulation, and restoring stomach balance ([@B115]). With the increasing tendency of Western countries to use statins, a group of drugs used to treat hyperlipidemia, RYR has attracted considerable research attention ([@B10]). RYR has been reported to possess numerous biological properties with hypolipidemic, anti-atherosclerotic, anti-cancer, neurocytoprotective, hepatoprotective, anti-osteoporotic, anti-fatigue, anti-diabetic, anti-obesity, immunomodulatory, anti-inflammatory, anti-hypertensive, and anti-microbial activities. RYR can also improve the quality of eggs. Chemical analyses have revealed that RYR contains monacolins, pigments, organic acids, amino acids, sterols, decalin derivatives, flavonoids, lignans, coumarin, terpenoids, and polysaccharides. However, only a few of these compounds have been screened in bioactivity assays, and their structures have not been sufficiently characterized. Although RYR is effective in treating various infections, the safety of its chemical constituents has not been defined. In addition, the quality control of RYR has not been investigated, and there is a lack of pharmacological information on the traditional uses of RYR.

In this article, we provide an up-to-date and comprehensive literature analysis of RYR and address its traditional uses, chemistry, pharmacological activities, possible molecular mechanisms, and safety. A critical evaluation of pharmacological studies in terms of the ethnomedical use of RYR was also performed. This information may provide new insights on RYR or its active ingredients, and help seek effective intervention strategies for the prevention and treatment of diseases, design clinical trials of bioactive compounds in RYR in future research, and develop fungal-medicines as well as edible products containing these functional properties.

Materials and Methods {#s2}
=====================

Information on studies involving RYR was gathered *via* the Internet using Google Scholar, Baidu Scholar, Elsevier, Web of Science, PubMed, CNKI, ScienceDirect, SciFinder, and Scopus, and a library search was performed of articles published in classic books of Chinese Herbal Medicine, local herbal encyclopedias, and Ph.D. and M.Sc. dissertations. The key words used were RYR, red mold rice, *M. purpureus*, secondary metabolites, chemistry, biological activity, pharmacology, medicinal use, safety, quality control, toxicology, and other related words ([@B178]). The MycoBank database (<http://mycobank.org>) was used to validate the scientific names of *M*. *purpureus*.

Mycology {#s3}
========

RYR ([**Figures S1A, B**](#SM1){ref-type="supplementary-material"}; also known as "*Hongqu*" or "*angkak*" in China, and '*red koji*' in Japan) is a remedy belonging to Traditional Chinese Medicine (TCM). Nowadays, it is also used as a dietary supplement in Western countries ([@B58]; [@B46]). It is produced by the fermentation of steamed rice with a food fungus of the *Monascus* genus, usually *M. purpureus* Went. Apart from *M. purpureus*, other related nonpathogenic molds of the *Monascus* genus, such as *M. ruber*, *M. anka*, and *M. pilosus*, are also used for RYR production in Japan, Korea, India, and Thailand ([@B23]; [@B60]). In TCM, however, *M. purpureus* is the only accepted medicinal fungus for RYR fermentation ([@B25]). According to the MycoBank database (<http://mycobank.org>), *M. purpureus* (MB\#235390) is the only accepted name for the fungus, and it has six synonyms, including *M. albidus* var. *albidus*, *M. anka* Nakaz. and K. Satô, *M. araneosus* K. Satô, *M. major* K. Satô, *M. rubiginosus* K. Satô, and *M. albidus* var. *glaber* K. Satô.

*M. purpureus*, which was largely described by Went in 1985, belongs to family Monascaceae, class Eurotiomycetes in Ascomycota ([@B65]). It can grow rapidly at a temperature of 25°C to 30°C on Potato Dextrose Agar or Luria Bertani mediums, and it favors conditions with a humidity of 65% to 85% ([**Figures S1C, D**](#SM1){ref-type="supplementary-material"}) ([@B69]). *M. purpureus* mostly breeds in asexual generation style, with many botryoid conidium. In general, stromata are solitary to gregarious, colony margins are short pulvinate to filiform, the ascocarp wall pectizes to membrane-like, ascospores are oval, the surface is smooth, and the color is red to nearly gray ([**Figures S1E, F**](#SM1){ref-type="supplementary-material"}) ([@B151]).

Traditional Uses {#s4}
================

RYR was first recorded in the Local Chronicles of Gutian (⟪古田县志⟫), which dates back to the Tang Dynasty (A.D. 618--907) ([@B103]). RYR has also been recorded in many ancient texts, such as Qing Yi Lu (⟪清异录⟫) (from the Five Dynasties and North Song Dynasty, A.D. 907--1127), Hai Lu Sui Shi (⟪海录碎事⟫) (Song Dynasty, A.D. 960--1279), and Tian Gong Kai Wu (⟪天工开物⟫) (Ming Dynasty, A.D. 1368--1644), and it is widely used in the Chinese culture as a food preservative, flavor enhancer, and food-coloring agent for fish sauces, rice wines, red soybean curd, pickled vegetables, and salted meats ([@B10]; [@B103]). In TCM, according to Materia Medica in Daily Use (⟪日用本草⟫) (Yuan Dynasty, A.D. 1271--1368) and the Compendium of Herbology (⟪本草纲目⟫) (A.D. 1552--1578), RYR is slightly mild and sweet, without significant toxicity, and it goes to the liver, spleen, and large intestines. It has been used to treat indigestion, diarrhea, blood circulation stasis, and limb weakness for more than 700 years ([@B25]; [@B125]). In some western countries, including the United States, Netherlands, and Italy, RYR has been used as an alternative to statin therapy, especially in patients who are intolerant to standardized therapy due to statin-associated myalgia or those who are opposed to taking statins ([@B24]).

RYR has been widely used in China as both food and medicine. RYR, as an ingredient, is found in more than 155 healthy foods, with purported curative powers ranging from reducing blood lipid levels and enhancing immunity to reducing blood pressure and alleviating fatigue (<http://www.da.yaozh.com>, last accessed on 28/07/2019). RYR-based products include *Hongqu Jiaonang*, *Yanjitangpai Kouyiling Ruanjiaonang*, and *Caizhiyuan Q* *~10~* *Ruanjiaonang*. Moreover, RYR has been used in at least 24 TCM preparations and at least 24 prescriptions for treating various chronic diseases (<http://www.da.yaozh.com>, last accessed on 28/07/2019). Commonly used Chinese herbal prescriptions containing RYR are listed in [**Table S1**](#SM3){ref-type="supplementary-material"}. "*Hong Qu Jiu*," "*Huo Tui Hong Qu San*," and "*Huang Lian Hong Qu Tang*" are Chinese prescriptions, whose use has been recorded in many ancient books, including the Compendium of Herbology (⟪本草纲目⟫), Following Traditional Customs Medical (⟪医学从众录⟫), and Gynecological Treatment of the Zhulin Temple (⟪竹林女科证治⟫). "*Xue Zhi Kang Pian*," "*Xue Zhi Kang Jiao Nang*," and "*Xin Huang Pian*" are folk medicines that have been accredited by the China State Food and Drug Administration. These entities are manufactured and sold in China to treat hyperlipemia, fatigue, and diarrhea ([@B25]).

Chemistry {#s5}
=========

RYR is comprised of various chemical constituents, including monacolins (**1**--**23**), pigments (**24**--**48**), organic acids (**49**--**55**), amino acids (**56**, **57**), sterols (**58**--**66**), decalin derivatives (**67**--**73**), flavonoids (**74**, **75**), lignans (**76**, **77**), coumarin (**78**), terpenoids (**79**--**83**), and others (**84**--**92**). In addition, polysaccharides, such as EPS-1, EPS-2, EPS-3, EPS-4, EPS-5, MPS-1, MPS-2, MPS-3, and monascan, have been isolated from RYR ([**Table 1**](#T1){ref-type="table"}). According to previously published chemical studies, monacolins and pigments are the most abundant and bioactive constituents in RYR. Among these, monacolins \[e.g. monacolin K (MK), also known as lovastatin\], and pigments (e.g. monascin, rubropunctatin, and rubropunctamine) have been extensively investigated and considered to have potential benefits.

###### 

Chemical constituents isolated from red yeast rice.

  Class                               Compound                                                                                                                                                           Molecular formula    CAS registry number   Reference(s)
  ----------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------- --------------------- -------------------------------------------------------------------------
  Monacolins                          Monacolin K (lovastatin) **1**                                                                                                                                     C~24~H~36~O~5~       75330-75-5            ([@B109]; [@B106]; [@B148]; [@B47]; [@B111]; [@B176]; [@B138]; [@B170])
                                      Monacolin L **2**                                                                                                                                                  C~19~H~28~O~3~       79394-47-1            ([@B109]; [@B176]; [@B163])
                                      Monacolin Q **3**                                                                                                                                                  C~19~H~22~O~2~       1879038-89-7          ([@B170])
                                      Monacolin R **4**                                                                                                                                                  C~19~H~28~O~3~       1879038-90-0          ([@B170])
                                      Monacolin S **5**                                                                                                                                                  C~24~H~38~O~7~       81693-02-9            ([@B170])
                                      Dehydromonacolin J **6**                                                                                                                                           C~19~H~26~O~3~       1355394-51-2          ([@B176])
                                      Dehydromonacolin K **7**                                                                                                                                           C~24~H~34~O~4~       109273-98-5           ([@B109]; [@B175]; [@B170])
                                      Dehydromonacolin L **8**                                                                                                                                           C~19~H~26~O~2~       1355394-52-3          ([@B175]; [@B170])
                                      Dehydromonacolin N **9**                                                                                                                                           C~21~H~28~O~4~       1355394-50-1          ([@B175])
                                      Dihydromonacolin K **10**                                                                                                                                          C~24~H~38~O~5~       77517-29-4            ([@B109]; [@B175]; [@B170])
                                      Dihydromonacolin L **11**                                                                                                                                          C~19~H~30~O~3~       86827-77-2            ([@B170])
                                      Dihydromonacolin-MV **12**                                                                                                                                         C~24~H~38~O~5~       935846-59-6           ([@B32])
                                      Dehydromonacolin-MV2 **13**                                                                                                                                        C~19~H~26~O~5~       1018346-91-2          ([@B33])
                                      Ethyl ester of monacolin K **14**                                                                                                                                  C~26~H~42~O~6~       77517-31-8            ([@B176])
                                      Methyl ester of the hydroxyl acid form of monacolin K **15**                                                                                                       C~25~H~40~O~6~       77934-80-6            ([@B109]; [@B176])
                                      Methyl ester of the hydroxy acid form of monacolin L **16**                                                                                                        C~20~H~32~O~4~       312710-94-4           ([@B109])
                                      α,β-Dehydromonacolin S **17**                                                                                                                                      C~24~H~36~O~6~       1879038-91-1          ([@B170])
                                      α,β-Hydromonacolin Q **18**                                                                                                                                        C~19~H~24~O~3~       118045-32-2           ([@B170])
                                      3α-Hydroxy-3,5-dihydromonacolin L **19**                                                                                                                           C~19~H~30~O~4~       119786-66-2           ([@B170])
                                      3β-Hydroxy-3,5-dihydromonacolin L **20**                                                                                                                           C~19~H~30~O~4~       1879038-92-2          ([@B170])
                                      α,β-Dehydrodihydromonacolin K **21**                                                                                                                               C~24~H~36~O~4~       312710-92-2           ([@B176]; [@B170])
                                      α,β-Dehydrodihydromonacolin L **22**                                                                                                                               C~19~H~28~O~2~       531523-94-1           ([@B176])
                                      (1S,2S,4aR,6S,8-S,8aS,3′S,5′R,2″S)-Methyl 1,2,4a,5,6,7,8,8a-octahydro-3′,5′-dihydroxy-2,6-dimethyl-8-\[(2-methyl-1-oxobutyl)oxy\]-1-naphthaleneheptanoate **23**   C~25~H~42~O~6~       101834-04-2           ([@B176])
  Pigments                            Rubropunctamine **24**                                                                                                                                             C~21~H~23~NO~4~      13552-06-2            ([@B153]; [@B154]; [@B155]; [@B2]; [@B43])
                                      Rubropunctatin **25**                                                                                                                                              C~21~H~22~O~5~       13471-84-6            ([@B153]; [@B154]; [@B155]; [@B2]; [@B163])
                                      Monascorubramine **26**                                                                                                                                            C~23~H~27~NO~4~      1003392-65-1          ([@B154]; [@B155]; [@B2]; [@B43])
                                      Monascorubrin **27**                                                                                                                                               C~23~H~26~O~5~       13283-85-7            ([@B154]; [@B155]; [@B2])
                                      Monascin **28**                                                                                                                                                    C~21~H~26~O~5~       3567-98-4             ([@B153]; [@B154]; [@B155]; [@B2]; [@B135]; [@B22]; [@B43])
                                      Ankaflavin **29**                                                                                                                                                  C~23~H~30~O~5~       50980-32-0            ([@B154]; [@B155]; [@B2]; [@B135]; [@B22]; [@B43])
                                      Xanthomonasin A **30**                                                                                                                                             C~21~H~24~O~7~       140375-37-7           ([@B154]; [@B2])
                                      Xanthomonasin B **31**                                                                                                                                             C~23~H~28~O~7~       146445-98-9           ([@B2])
                                      Monankarin A **32**                                                                                                                                                C~20~H~22~O~6~       182161-52-0           ([@B61]; [@B154])
                                      Monasfluore A **33**                                                                                                                                               C~21~H~24~O~5~       1004537-75-0          ([@B66]; [@B21]; [@B63]; [@B43])
                                      Monasfluore B **34**                                                                                                                                               C~23~H~28~O~5~       1004537-76-1          ([@B66]; [@B21]; [@B63]; [@B43])
                                      Monapurone A **35**                                                                                                                                                C~20~H~26~O~4~       1263777-47-4          ([@B95])
                                      Monapurone B **36**                                                                                                                                                C~21~H~28~O~4~       1263777-50-9          ([@B95])
                                      Monapurone C **37**                                                                                                                                                C~21~H~28~O~4~       1263777-48-5          ([@B95])
                                      Monascopyridine A **38**                                                                                                                                           C~21~H~25~NO~4~      604786-54-1           ([@B155]; [@B43])
                                      Monascopyridine B **39**                                                                                                                                           C~23~H~29~NO~4~      604786-55-2           ([@B155]; [@B43])
                                      Monascopyridine C **40**                                                                                                                                           C~20~H~27~NO~3~      909094-27-5           ([@B79]; [@B63]; [@B43])
                                      Monascopyridine D **41**                                                                                                                                           C~22~H~31~NO~3~      909094-28-6           ([@B79]; [@B63]; [@B43])
                                      Monascopyridine E **42**                                                                                                                                           C~21~H~27~NO~4~      1313735-11-3          ([@B43])
                                      Monascopyridine F **43**                                                                                                                                           C~23~H~31~NO~4~      1313735-13-5          ([@B43])
                                      Monapurfluore A **44**                                                                                                                                             C~23~H~32~O~4~       1259424-24-2          ([@B63])
                                      Monapurfluore B **45**                                                                                                                                             C~23~H~32~O~4~       1259424-22-0          ([@B63])
                                      4-\[2,4-Dihydroxy-6-(3-hydroxybutanethioyloxy)-3-methylphenyl\]-3,4-dihydroxy-3,6-dimethylheptanoic acid **46**                                                    C~20~H~30~O~8~S      910788-93-1           ([@B11])
                                      9-Hexanoyl-3-(2-hydroxypropyl)-6a-methyl-9,9a-dihydro-6H-furo\[2,3-h\]isochromene-6,8(6aH)-dione **47**                                                            C~21~H~26~O~6~       910788-92-0           ([@B11])
                                      Monapilosusazaphilone **48**                                                                                                                                       C~23~H~32~O~5~       1444202-34-9          ([@B23]; [@B170])
  Organic acids and amino acids       Linoleic acid **49**                                                                                                                                               C~18~H~32~O~2~       60-33-3               ([@B171])
                                      α-Linolenic acid **50**                                                                                                                                            C~18~H~30~O~2~       463-40-1              ([@B171])
                                      Citrinin **51**                                                                                                                                                    C~13~H~14~O~5~       1086-03-9             ([@B153]; [@B154]; [@B155])
                                      1-Heptadecanecarboxylic acid **52**                                                                                                                                C~18~H~36~O~2~       57-11-4               ([@B138])
                                      1-Pentadecanecarboxylic acid **53**                                                                                                                                C~16~H~32~O~2~       57-10-3               ([@B138])
                                      2-Hydroxyoctadecanoic acid **54**                                                                                                                                  C~18~H~36~O~3~       629-22-1              ([@B138])
                                      5-(2′-Hydroxy-6′-methyl phenyl)-3-methylfuran-2-carboxylic acid **55**                                                                                             C~13~H~12~O~4~       2060554-52-9          ([@B71])
                                      (+)-Monascumic acid **56**                                                                                                                                         C~10~H~17~NO~4~      673477-38-8           ([@B1]; [@B2])
                                      (−)-Monascumic acid **57**                                                                                                                                         C~10~H~17~NO~4~      673477-39-9           ([@B1]; [@B2])
  Sterols                             Ergosterol **58**                                                                                                                                                  C~28~H~44~O          57-87-4               ([@B22]; [@B148]; [@B47]; [@B138])
                                      Stigmasterol **59**                                                                                                                                                C~29~H~48~O          83-48-7               ([@B148]; [@B47]; [@B138])
                                      β-Sitosterol **60**                                                                                                                                                C~29~H~50~O          83-46-5               ([@B138])
                                      3β-Hydroxylstigmast-5-en-7-one **61**                                                                                                                              C~29~H~48~O~2~       2034-74-4             ([@B23])
                                      3β-Hydroxystigmasta-5,22-dien-7-one **62**                                                                                                                         C~29~H~46~O~2~       36449-99-7            ([@B23])
                                      6β-Hydroxystigmast-4-en-3-one **63**                                                                                                                               C~29~H~48~O~2~       36450-02-9            ([@B23])
                                      6β-Hydroxystigmasta-4,22-dien-3-one **64**                                                                                                                         C~29~H~46~O~2~       36450-01-8            ([@B23])
                                      Daucosterol **65**                                                                                                                                                 C~35~H~60~O~6~       474-58-8              ([@B138])
                                      β-Sitosteryl palmitate **66**                                                                                                                                      C~44~H~76~O~2~       110716-42-2           ([@B22])
  Decalin derivatives                 Monascusic acid A **67**                                                                                                                                           C~15~H~22~O~2~       1364517-38-3          ([@B169]; [@B175])
                                      Monascusic acid B **68**                                                                                                                                           C~15~H~22~O~2~       1364517-30-5          ([@B175])
                                      Monascusic acid C **69**                                                                                                                                           C~15~H~22~O~2~       1364517-32-7          ([@B175])
                                      Monascusic acid D **70**                                                                                                                                           C~15~H~20~O~2~       1364517-35-0          ([@B175])
                                      Monascusic acid E **71**                                                                                                                                           C~15~H~20~O~2~       1364517-37-2          ([@B175])
                                      Monascusic lactone A **72**                                                                                                                                        C~15~H~20~O~2~       1364517-28-1          ([@B175])
                                      Heptaketide **73**                                                                                                                                                 C~15~H~24~O~2~       531523-95-2           ([@B175]; [@B170])
  Flavonoids, lignans, and coumarin   Daidzein **74**                                                                                                                                                    C~15~H~10~O~4~       486-66-8              ([@B71])
                                      Genistein **75**                                                                                                                                                   C~15~H~10~O~5~       446-72-0              ([@B71])
                                      5,5′-Dimethoxylariciresinol **76**                                                                                                                                 C~22~H~28~O~8~       116498-58-9           ([@B23])
                                      Lariciresinol **77**                                                                                                                                               C~20~H~24~O~6~       27003-73-2            ([@B23])
                                      Scopoletin **78**                                                                                                                                                  C~10~H~8~O~4~        92-61-5               ([@B23])
  Terpenoids                          3-*epi*-Betulinic acid **79**                                                                                                                                      C~30~H~48~O~3~       472-15-1              ([@B21])
                                      3-*epi*-Betulinic acid acetate **80**                                                                                                                              C~32~H~50~O~4~       10376-50-8            ([@B21])
                                      Friedelan-3-one **81**                                                                                                                                             C~30~H~50~O          559-74-0              ([@B21])
                                      α-Cadinol **82**                                                                                                                                                   C~15~H~26~O          481-34-5              ([@B21])
                                      Anticopalol **83**                                                                                                                                                 C~20~H~34~O          10395-43-4            ([@B21])
  Polysaccharides                     EPS-1, EPS-2, EPS-3, EPS-4, EPS-5                                                                                                                                  ---                  ---                   ([@B72])
                                      MPS-1, MPS-2, MPS-3                                                                                                                                                ---                  ---                   ([@B72])
                                      Monascan                                                                                                                                                           ---                  ---                   ([@B140])
  Other compounds                     Peroxymonascuspyrone **84**                                                                                                                                        C~19~H~30~O~6~       2227383-92-6          ([@B21])
                                      α-Tocospiro A **85**                                                                                                                                               C~29~H~50~O~4~       601490-40-8           ([@B21])
                                      Spathulenol **86**                                                                                                                                                 C~15~H~24~O          6750-60-3             ([@B78]; [@B21])
                                      Monascodilone **87**                                                                                                                                               C~15~H~12~O~4~       439668-12-9           ([@B153]; [@B154])
                                      Monascustin **88**                                                                                                                                                 C~10~H~18~N~2~O~3~   2083632-09-9          ([@B150])
                                      N-*cis*-feruloylmethoxytyramine **89**                                                                                                                             C~19~H~21~NO~5~      78510-19-7            ([@B23])
                                      Monaspurpurone **90**                                                                                                                                              C~13~H~14~O~5~       1262840-98-1          ([@B22])
                                      *p*-Nitrophenol **91**                                                                                                                                             C~6~H~5~NO~3~        100-02-7              ([@B22])
                                      1-Dotriacontanol **92**                                                                                                                                            C~32~H~66~           544-85-4              ([@B138])

Dash (---) denotes no useful information found in the study.

Monacolins {#s5_1}
----------

Monacolins are one of the main active ingredients in RYR. In total, twenty-three monacolins have been isolated from RYR, including MK **1**, monacolin L **2** ([@B109]), monacolin Q **3**, monacolin R **4**, monacolin S **5** ([@B170]), mehydromonacolin J **6** ([@B176]), dehydromonacolin K **7**, dehydromonacolin L **8**, dehydromonacolin N **9**, dihydromonacolin K **10**, dihydromonacolin L **11** ([@B109]; [@B175]; [@B170]), dihydromonacolin-MV **12**, dehydromonacolin-MV2 **13** ([@B32]; [@B33]), ethyl ester of MK **14**, methyl ester of the hydroxyl acid form of MK **15**, methyl ester of the hydroxy acid form of monacolin L **16** ([@B109]; [@B176]), α,β-dehydromonacolin S **17**, α,β-hydromonacolin Q **18**, 3α-hydroxy-3,5-dihydromonacolin L **19**, 3β-hydroxy-3,5-dihydromonacolin L **20**, α,β-dehydrodihydromonacolin K **21**, α,β-dehydrodihydromonacolin L **22**, and (1S,2S,4aR,6S,8-S,8aS,3′S,5′R,2″S)-methyl 1,2,4a,5,6,7,8,8a-octahydro-3′,5′-dihydroxy-2,6-dimethyl-8-\[(2-methyl-1-oxobutyl)oxy\]-1-naphthaleneheptanoate **23** ([@B176]; [@B170]). Monacolins, especially RYR-derived MK, have been shown to have remarkable hypolipidemic effects ([@B19]) as well as anti-osteoporotic ([@B51]), and anti-fatigue ([@B19]) activities. The chemical structures of these monacolins are shown in [**Figures 1**](#f1){ref-type="fig"} and [**2**](#f2){ref-type="fig"}.

![Monacolins isolated from RYR (I).](fphar-10-01449-g001){#f1}

![Monacolins isolated from RYR (II).](fphar-10-01449-g002){#f2}

Pigments {#s5_2}
--------

Pigments are also important active compounds found in RYR. Twenty-five pigments have been isolated from RYR, including rubropunctamine **24**, rubropunctatin **25**, monascorubramine **26**, monascorubrin **27**, monascin **28**, ankaflavin **29**, xanthomonasin A **30**, xanthomonasin B **31**, monankarin A **32** ([@B154]; [@B2]), monasfluore A **33**, monasfluore B **34** ([@B66]), monapurone A **35**, monapurone B **36**, monapurone C **37** ([@B95]), monascopyridine A **38**, monascopyridine B **39**, monascopyridine C **40**, monascopyridine D **41**, monascopyridine E **42**, monascopyridine F **43** ([@B43]), monapurfluore A **44**, monapurfluore B **45** ([@B63]), 4-\[2,4-dihydroxy-6-(3-hydroxybutanethioyloxy)- 3-methylphenyl\]-3,4-dihydroxy-3,6-dimethylheptanoic acid **46**, 9-hexanoyl-3-(2-hydroxypropyl)-6a-methyl-9,9a-dihydro-6H-furo\[2,3-h\]isochromene-6,8(6aH)-dione **47** ([@B11]), and monapilosusazaphilone **48** ([@B23]). RYR-derived pigments possess hypolipidemic effects ([@B174]) as well as anti-cancer ([@B163]), anti-fatigue ([@B19]), and anti-inflammatory ([@B63]) activities. In addition, RYR pigments can be used to color yogurt red ([@B17]). The chemical structures of these molecules are shown in [**Figures 3**](#f3){ref-type="fig"} and [**4**](#f4){ref-type="fig"}.

![Pigments isolated from RYR (I).](fphar-10-01449-g003){#f3}

![Pigments isolated from RYR (II).](fphar-10-01449-g004){#f4}

Organic Acids and Amino Acids {#s5_3}
-----------------------------

Seven organic acids, including linoleic acid **49**, α-linolenic acid **50** ([@B171]), citrinin **51** ([@B154]), 1-heptadecanecarboxylic acid **52**, 1-pentadecanecarboxylic acid **53**, 2-hydroxyoctadecanoic acid **54** ([@B138]), and 5-(2′-hydroxy-6′-methyl phenyl)-3-methylfuran-2-carboxylic acid **55** ([@B71]), as well as (+)-monascumic acid **56** and (−)-monascumic acid **57**, two amino acids ([@B1]; [@B2]), have been isolated from RYR. However, RYR-derived citrinin has been reported to have lethal effects on the kidney, and it may also act as a teratogen (harmful to the embryo or fetus) and genotoxin at high concentrations in cultured human lymphocytes ([@B125]). In addition, the two amino acids have been shown to have potent inhibitory effects on Epstein-Barr virus early antigen (EBV-EA) activation ([@B2]).

Sterols {#s5_4}
-------

Nine sterols (ergosterol **58**, stigmasterol **59**, β-sitosterol **60**, 3β-hydroxylstigmast-5-en-7-one **61**, 3β-hydroxystigmasta-5,22-dien-7-one **62**, 6β-hydroxystigmast-4-en-3-one **63**, 6β-hydroxystigmasta-4,22-dien-3-one **64**, daucosterol **65**, and β-sitosteryl palmitate **66**) were isolated from RYR ([@B22]; [@B148]; [@B23]; [@B138]). Among these, stigmasterol has been reported to possess hypolipidemic effects ([@B148]).

Decalin Derivatives {#s5_5}
-------------------

Seven decalin derivatives, including monascusic acid A **67**, monascusic acid B **68**, monascusic acid C **69**, monascusic acid D **70**, monascusic acid E **71**, monascusic lactone A **72**, and heptaketide **73** were isolated from RYR ([@B169]; [@B175]; [@B170]). These decalin derivatives could suppress human T cell proliferation in a dose-dependent manner from 10 µmol/L to 100 µmol/L ([@B175]). The chemical structures of these decalin derivatives are shown in [**Figure 5**](#f5){ref-type="fig"}.

![Decalin derivatives isolated from RYR.](fphar-10-01449-g005){#f5}

Flavonoids, Lignans, Coumarin, and Terpenoids {#s5_6}
---------------------------------------------

Two flavonoids, including daidzein **74** and genistein **75** ([@B71]), two lignans, including 5,5′-dimethoxylariciresinol **76** and lariciresinol **77**, and one coumarin (scopoletin **78**) ([@B23]), as well as five terpenoids, including 3-*epi*-betulinic acid **79**, 3-*epi*-betulinic acid acetate **80**, Friedelan-3-one **81**, α-cadinol **82**, and anticopalol **83** ([@B21]), have been isolated from RYR. Presently, there are few studies investigating the pharmacological activities of these RYR-derived compounds.

Polysaccharides {#s5_7}
---------------

Nine polysaccharides, including EPS-1, EPS-2, EPS-3, EPS-4, EPS-5, MPS-1, MPS-2, MPS-3, and monascan, were isolated from RYR ([@B140]; [@B72]). These polysaccharides are all composed of mannose, glucose, and galactose. EPS-1, EPS-2, EPS-3, EPS-4, and EPS-5 are composed of mannose, glucose, and galactose at a molar ratio of 0.364:0.415:0.221, whereas MPS-1, MPS-2, and MPS-3 are composed of mannose, glucose, and galactose at a molar ratio of 0.500:0.318:0.192 ([@B72]). Monacan, a homogeneous polysaccharide with a molecular weight of ∼400,000 Da, is composed of mannose, glucose, and galactose at a molar ratio of 1:2:4, and its backbone is comprised of 1→3, 1→2, and 1→6 glucosidic bonds ([@B140]). Moreover, RYR-derived polysaccharides have been reported to possess anti-cancer ([@B36]) and immunomodulatory ([@B168]) activities.

Other Constituents {#s5_8}
------------------

Nine other compounds, including peroxymonascuspyrone **84**, α-tocospiro A **85**, spathulenol **86** ([@B21]), monascodilone **87** ([@B153]; [@B154]), monascustin **88** ([@B150]), N-*cis*-feruloylmethoxytyramine **89** ([@B23]), monaspurpurone **90**, *p*-nitrophenol **91** ([@B22]), and 1-dotriacontanol **92** ([@B138]), were isolated from RYR. The chemical structures of these compounds are shown in [**Figure 6**](#f6){ref-type="fig"}.

![Other constituents isolated from RYR.](fphar-10-01449-g006){#f6}

Pharmacological Activities {#s6}
==========================

RYR has been the subject of several pharmacological investigations due to its various ethnomedicinal uses. Studies have demonstrated that RYR exhibits a wide range of biological properties with hypolipidemic, anti-atherosclerotic, anti-cancer, neurocytoprotective, hepatoprotective, anti-osteoporotic, anti-fatigue, anti-diabetic, anti-obesity, immunomodulatory, anti-inflammatory, and anti-hypertensive activities. Among these, hypolipidemic and anti-atherosclerotic activities are most pronounced given that RYR is thought to play curative roles in resolving turbidity, invigorating blood circulation, and resolving blood stasis. These effects are summarized in [**Table 2**](#T2){ref-type="table"} and discussed in greater detail in the following sections. The relationships between the doses of RYR and its medicinal properties are shown in [**Figure 7**](#f7){ref-type="fig"}.

###### 

Pharmacological activities of red yeast rice.

  ------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ----------------------------------- ------------------
  **Pharmacological activity**               **Tested substance**                                                     **Model**                                                                  **Tested living system/organ/cell**                         **Result**                                                                                                                                                                                                                                     **Dose range**         **Time period of application**      **Reference(s)**
  Hypolipidemic effect                       Monacolin K                                                              High fat diet fed mice                                                     Liver and serum                                             Improved serum HDL-C level, decreased serum TC, TG, LDL-C levels, and up-regulated liver LPL mRNA and LDLR mRNA expression                                                                                                                     5--30 mg/kg            6 weeks                             ([@B19])
                                             Pigments                                                                 High fat diet fed mice                                                     Liver and serum                                             Improved serum HDL-C level, decreased serum TG, LDL-C levels, and up-regulated liver LPL mRNA and LDLR mRNA expression                                                                                                                         10--100 mg/kg          6 weeks                             ([@B19])
                                             Pigments                                                                 High fat diet fed mice                                                     Liver, blood, epididymal adipose, and fresh fecal samples   Ameliorated serum lipid levels, suppressed hepatic lipid accumulation and steatosis, and modulated the relative abundance of functionally related microbial phylotypes                                                                         20 mg/kg               8 weeks                             ([@B174])
                                             Red yeast rice capsule                                                   Healthy people with hyperlipidemia                                         Blood                                                       Reduced TC, LDL-C, and total triacylglycerol concentrations                                                                                                                                                                                    48 mg/kg               8 weeks                             ([@B52])
                                             Red yeast rice capsule                                                   Atherogenic diet fed rabbit                                                Blood and aortas                                            Reduced serum TG                                                                                                                                                                                                                               0.4--1.35 g/kg         200 days                            ([@B149])
                                             Aqueous extracts                                                         High fat diet fed mice                                                     Blood                                                       Alleviated blood lipid parameters                                                                                                                                                                                                              1--2.5 g/kg            8--12 weeks                         ([@B91])
                                             Red yeast rice powder                                                    Hamsters                                                                   Blood and feces                                             Reduced plasma TC and triacylglycerol, increased excretion of fecal acidic sterols                                                                                                                                                             1--3 g/kg              6 weeks                             ([@B110])
                                             Red yeast rice capsule                                                   Dyslipidemia patients                                                      Blood                                                       Decreased TC and LDL-C levels                                                                                                                                                                                                                  36 mg/kg               24 weeks                            ([@B6])
                                             Red yeast rice capsule                                                   Patients screened                                                          Blood                                                       Decreased TC and LDL-C levels                                                                                                                                                                                                                  ---                    16 weeks                            ([@B8])
                                             Red yeast rice capsule                                                   Dyslipidemia patients induced by second-generation antipsychotics (SGAs)   Blood                                                       Decreased LDL-C level                                                                                                                                                                                                                          4 mg/kg                30 days                             ([@B9])
                                             Red yeast rice capsule                                                   High cholesterol diet fed mice                                             Blood                                                       Down-regulated TG, TC, and LDL−C levels, and up-regulated HDL-C level                                                                                                                                                                          300 mg/kg              6 weeks                             ([@B35])
                                             Red yeast rice capsule                                                   Lean and healthy people                                                    Blood                                                       Reduced TC, LDL-C, Hs-CRP, and PWV levels                                                                                                                                                                                                      12 mg/kg               4 weeks                             ([@B104])
                                             Monacolins                                                               Healthy, mildly hypercholesterolemic people                                Plasma                                                      Reduced TC, LDL-C, non--high density lipoprotein cholesterol, matrix metalloproteinase 2/9 levels                                                                                                                                              0.2 mg/kg              4 weeks                             ([@B28])
                                             Red rice yeast capsule                                                   Hyperlipidemia patients                                                    Blood                                                       Increased adiponectin and lowered LDL-C and TC levels                                                                                                                                                                                          12 mg/kg               8 weeks                             ([@B90])
  Anti-atherosclerotic activity              Aqueous and ethanol extracts                                             Bone marrow-derived proangiogenic cells (PACs)                             PACs                                                        Inhibited β-galactosidase activation, reduced oxidative stress, and improved heme oxygenase-1 level                                                                                                                                            12.5--50 μg/mL         12--48 h                            ([@B107])
                                             Aqueous and ethanol extracts                                             Tumor necrosis factor (TNF)-α-treated human aortic smooth muscle cells     HASMCs                                                      Reduced TNF-α-stimulated MMP-2 and MMP-9 expression, down-regulated NF-κB activation and intracellular ROS formation                                                                                                                           1--160 μg/mL           24 h                                ([@B101])
                                             Aqueous and ethanol extracts                                             Homocysteine treated human aortic endothelial cells                        HAECs                                                       Reduced HCY-stimulated endothelial adhesiveness, and down-regulated intracellular ROS formation                                                                                                                                                1--50 μg/mL            24 h                                ([@B100])
                                             Red yeast rice (XZK) powder                                              C57BL/6 mice                                                               Mice and carotid arteries                                   Inhibited vulnerable plaque progression, decreased plaque area, and suppressed lesional endoplasmic reticulum stress                                                                                                                           600--1200 mg/kg        8 weeks                             ([@B132])
                                             Red yeast rice                                                           High fat diet fed mice                                                     Heart, aortas, and plasma                                   Reduced plaque size, stabilized plaque, protected endothelium, and decreased number of lipid droplets and cholesterol calculi, and the levels of Hs-CRP, IL-6, and TNF-α                                                                       120 mg/kg              36 weeks                            ([@B161])
                                             Red yeast rice (XZK) powder                                              RAW264.7 cells                                                             RAW264.7 cells                                              Reduced nicotinamide adenine dinucleotide phosphate oxidase activity, decreased membrane translocation of p47^phox^, and inhibited extracellular signal-regulated kinase 1/2 activity                                                          25--100 μg/mL          2 h                                 ([@B96])
  Anti-cancer activity                       Red yeast rice capsule                                                   Breast cancer patients                                                     Breast cancer patients and their serum                      Improved living quality, and decreased CA125, CA153, VEGF, and VEGFR2 levels                                                                                                                                                                   120 mg/kg              12 weeks                            ([@B173])
                                             Aqueous extracts                                                         HUVEC cells                                                                HUVEC cells                                                 Inhibited cells proliferation and migration, and decreased VEGFR2 mRNA expression level                                                                                                                                                        10--50 μg/mL           24 h                                ([@B173])
                                             Ethanol, and ethyl acetate extracts                                      MCF-7 human breast cancer cells                                            MCF-7 cells                                                 Exhibited direct cytotoxic and proapoptotic effects                                                                                                                                                                                            50--150 μg/mL          24--48 h                            ([@B89])
                                             Methanol extracts                                                        Caco-2 human colorectal adenocarcinoma cells                               Caco-2 cells                                                Exhibited antiproliferative effect, deregulated some proteins expression                                                                                                                                                                       1--100 μmol/L (MK)     24 h                                ([@B99])
                                             Polysaccharides                                                          Replanted S~180~ tumor mice                                                Mice and their tumor, spleen                                Inhibited tumor growth, and improved body weight                                                                                                                                                                                               800 mg/kg              2 weeks                             ([@B36])
                                             Rubropunctatin                                                           K-562, SK-OV-3, and SNU-1 cells                                            K-562, SK-OV-3, and SNU-1 cells                             Exhibited telomerase inhibitory effects by down-regulating gene expression of telomerase-related protein hTERT                                                                                                                                 1.25--40 μg/mL         48 h                                ([@B163])
                                             Monacolin L                                                              K-562, SK-OV-3, and SNU-1 cells                                            K-562, SK-OV-3, and SNU-1 cells                             Inhibited cancer cells proliferation and induced apoptosis                                                                                                                                                                                     1.25--40 μg/mL         48 h                                ([@B163])
                                             Methylene chloride extracts                                              LNCaP human PCa cells                                                      LNCaP human PCa cells                                       Inhibited cancer cell growth                                                                                                                                                                                                                   6--150 μg/mL           48--72 h                            ([@B57])
                                             Red yeast rice powder                                                    SCID tumor mice induced by human prostate cancer cells                     Tumor and serum                                             Reduced tumor volumes, decreased serum PSA levels, and gene expression of androgen synthesizing enzymes (HSD3B2, AKR1C3, and SRD5A1)                                                                                                           ---                    ---                                 ([@B59])
                                             Methylene chloride extracts                                              HCT-116 and HT-29 human colon cancer cells                                 HCT-116 and HT-29 cells                                     Inhibited both tumor cell growths and enhanced apoptosis                                                                                                                                                                                       20--300 μg/mL          24--72 h                            ([@B58])
                                             Ankaflavin                                                               HepG2 and A549 cells                                                       HepG2 and A549 cells                                        Stimulated apoptosis                                                                                                                                                                                                                           15--30 μg/mL           48 h                                ([@B135])
                                             Monapurfluores A and B, monascopyridines C and D                         HepG2 and WiDr cell lines                                                  HepG2 and WiDr cell lines                                   Inhibited cell growth                                                                                                                                                                                                                          6.26--100 μg/mL        72 h                                ([@B63])
  Neurocytoprotective activity               Ethanol extracts                                                         Neuronally differentiated PC12 cells                                       PC12 cells                                                  Provided stronger neuroprotection, and repressed inflammatory response and oxidative stress.                                                                                                                                                   10--25 μg/mL           48 h                                ([@B85])
                                             Ethanol extracts                                                         SD rats induced by Amyloid β, water maze, and passive avoidance tasks      Rats, cerebral cortex, and hippocampus                      Reversed memory deficit, prevented amyloid β fibrils from being formed and deposited in hippocampus and further decrease Aβ40 accumulation                                                                                                     151--755 mg/kg         4 weeks                             ([@B85])
                                             Red yeast rice power                                                     Zn-deficient diet fed rats, water maze, and passive avoidance tasks        Rats, cortex, hippocampus, and blood                        Improved antioxidant enzyme activities and neural activity to maintain cortex and hippocampus functions                                                                                                                                        151--755 mg/kg         4 weeks                             ([@B86])
                                             Lovastatin derivatives                                                   PC12 cells induced by 6-OHDA                                               PC12 cells                                                  Reduced apoptosis, caspase-3, -8, and -9 activities and intracellular calcium concentrations, stabilized mitochondrial membrane potential                                                                                                      12.5--100 μmol/L       24 h                                ([@B102])
                                             Ethanol extracts                                                         Human neuroblastoma IMR32 cells induced by cholesterol                     IMR32 cells                                                 Suppressed cholesterol raised β-secretase activity, increased sAPPR secretion                                                                                                                                                                  10--50 μg/mL           48 h                                ([@B87])
                                             Red yeast rice power                                                     Rats, water maze and passive avoidance tasks.                              Rats, blood, and brain                                      Reversed the memory deficit, decreased thiobarbituric acid reactive substances and reactive oxygen species                                                                                                                                     151--755 mg/kg         4 weeks                             ([@B87])
  Hepatoprotective effect                    Red yeast rice power                                                     Chronic alcohol-induced mice                                               Liver, kidney, and blood                                    Attenuated the increased serum transaminases levels, hepatic triglyceride and TC accumulation, elevated hepatic antioxidant ability, reduced hepatic cell damage (steatosis), and decreased tissue inflammatory cytokine levels                307.5--1,537.5 mg/kg   5 weeks                             ([@B20])
                                             Red yeast rice power                                                     High cholesterol diet fed mice                                             Liver and serum                                             Reduced insulin resistance, inhibited TNF-α expression, and increased PPARα mRNA and proteins expression levels                                                                                                                                0.17--1 g/kg           8 weeks                             ([@B108])
                                             Red yeast rice (XZK) capsule                                             High fat diet fed mice                                                     Liver and blood                                             Ameliorated dyslipidemia and fat accumulation in the liver; improved insulin resistance and ameliorated oxidative stress; lessened hepatic steatosis, necro-inflammation, and collagen deposition; and inhibited hepatic expression of TNF-α   300 mg/kg              6 weeks                             ([@B56])
                                             Red yeast rice power                                                     Zn-deficient rats                                                          Liver and blood                                             Inhibited serum ALT levels, increased hepatic antioxidase activity, suppressed the productions of ROS and proinflammatory cytokines                                                                                                            151--755 mg/kg         4 weeks                             ([@B88])
  Anti-osteoporotic activity                 Red yeast rice power                                                     Bone defects rabbits                                                       Rabbits                                                     Promoted new bone formation                                                                                                                                                                                                                    5.0--5.7 mg/kg         ---                                 ([@B157])
                                             Red yeast rice extracts                                                  UMR 106 cells                                                              UMR 106 cells                                               Increased the optical density in the MTT assay and ALP activity                                                                                                                                                                                1--10 mg/mL            24--72 h                            ([@B157])
                                             Methanol extracts                                                        Osteoblast-like MC3T3-E1 cells                                             MC3T3-E1 cells                                              Stimulated cell proliferation and ALP activity                                                                                                                                                                                                 0.001--1.0 mg/mL       24 h, 5--25 days                    ([@B26])
                                             Ethanol extracts                                                         Ovariectomy-induced bone loss rats                                         Femora and serum                                            Increased the bone mineral density, decreased the levels of bone turnover markers, including osteocalcin and tartrate resistant acid phosphatase activity                                                                                      1.56--6.24 g/kg        20 weeks                            ([@B146])
                                             Ethanol extracts                                                         Osteoblast cells                                                           Osteoblast cells                                            Improved the osteoblast viabilities, enhanced the expression of Bmp2 and Bmp4 both at the mRNA and protein levels                                                                                                                              ---                    48 h                                ([@B146])
                                             Methanol extracts                                                        SD rats                                                                    Bones                                                       Stimulated new bone formation                                                                                                                                                                                                                  125--500 mg/kg         5 days or 2 days/week for 5 weeks   ([@B51])
  Anti-fatigue activity                      Monacolin K                                                              Mice and swimming test                                                     Liver and serum                                             Improved hepatic glycogen level, decreased serum urea nitrogen level, and increased swimming time                                                                                                                                              10--90 mg/kg           30 days                             ([@B19])
                                             Pigments                                                                 Mice and swimming test                                                     Liver and serum                                             Improved hepatic glycogen level, decreased serum urea nitrogen level, and increased swimming time                                                                                                                                              50--200 mg/kg          30 days                             ([@B19])
                                             Aqueous extracts                                                         Mice and swimming test                                                     Mice                                                        Increased swimming time                                                                                                                                                                                                                        100 mg/kg              30 days                             ([@B19])
                                             Ethanol extracts                                                         Mice and swimming test                                                     Liver and serum                                             Improved hepatic glycogen level, decreased serum urea nitrogen level, and increased swimming time                                                                                                                                              100 mg/kg              30 days                             ([@B19])
                                             Red yeast rice pills                                                     Dyslipidemia patients                                                      Psychological and physical questionnaires                   Induced less muscle fatigue and remained physical activity                                                                                                                                                                                     24 mg/kg               4 weeks                             ([@B165])
                                             Red yeast rice power                                                     Wistar rats and swimming endurance test                                    Rats and blood                                              Exhibited higher exercise time and blood glucose concentration, lowered blood lactate, blood urea nitrogen, and hemoglobin                                                                                                                     1--5 g/kg              4 weeks                             ([@B143])
  Anti-diabetic activity                     Red yeast rice powder                                                    Rats                                                                       Blood                                                       Raised the release of ACh from nerve terminals, stimulated muscarinic M3 receptors, augmented the insulin release, and lowered plasma glucose                                                                                                  50--150 mg/kg          90 min                              ([@B13])
                                             Red yeast rice                                                           Diabetic rats induced by streptozotocin                                    Rats, liver, and blood                                      Lowered plasma glucose, mRNA levels of phosphoenolpyruvate carboxykinase in liver, and reversed hyperphagia                                                                                                                                    50--350 mg/kg          2 weeks                             ([@B12])
                                             Red yeast rice (XZK)                                                     Diabetic mice                                                              Blood, islet, and pancreas                                  Decreased blood glucose level, improved glucose tolerance and insulin secretion, protected islets                                                                                                                                              300 mg/kg              8 weeks                             ([@B145])
  Anti-obesity activity                      Red yeast rice                                                           High fat diet fed mice                                                     Perirenal and epididymal fat pads, blood                    Exhibited lower weight gain and less fat pads mass, increased the lipolysis activity of adipose tissue, and reduced food/energy consumption                                                                                                    4--20 g/kg             6 weeks                             ([@B15])
                                             Aqueous and ethanol extracts                                             3T3-L1 cells                                                               3T3-L1 cells                                                Suppressed the proliferation and differentiation, enhanced the lipolysis activity                                                                                                                                                              50--200 μg/mL          24--48 h                            ([@B15])
                                             Aqueous extracts                                                         High fat diet fed mice                                                     Mice                                                        Prevented weight gain, reduced the mesenteric fat pad weight                                                                                                                                                                                   1--2.5 g/kg            8--12 weeks                         ([@B91])
  Anti-inflammatory activity                 Red yeast rice capsule                                                   High cholesterol diet fed mice                                             Kidney and serum                                            Reduced the expression levels of TNF−α and IL-6, and repaired kidney damage                                                                                                                                                                    300 mg/kg              6 weeks                             ([@B35])
                                             Monascusazaphilone A                                                     RAW264.7 cells                                                             RAW264.7 cells                                              Inhibited NO production                                                                                                                                                                                                                        1--20 μg/mL            24 h                                ([@B160])
                                             Monapurfluores A and B, monascopyridines C and D, monasfluores A and B   RAW264.7 cells induced by lipopolysaccharide                               RAW264.7 cells                                              Inhibited NO production                                                                                                                                                                                                                        5--20 μg/mL            12 h                                ([@B63])
  Anti-hypertensive activity                 Ethanol extracts                                                         Spontaneously hypertensive rats                                            Rats and blood                                              Exhibited anti-hypertensive effects, decreased heart rate, cardiac contractility, and sympathetic vasomotor tone, increased plasma NO production                                                                                               10--50 mg/kg           30--120 min                         ([@B144])
  Immunomodulatory activity                  Polysaccharides                                                          Mice                                                                       Thymus, spleen, foot, and blood                             Improve phagocytic ability of abdominal cavity macrophage, prompted the formation of periphery blood E-rose loop, increased the transformation rate of lymphocyte, and strengthened nonspecific immunity                                       50--300 mg/kg          7--14 days                          ([@B168])
  Improving production and quality of eggs   Red yeast rice powder                                                    Laying hens                                                                Blood and eggs                                              Increased laying rate, albumen height, haugh units, and serum calcium levels, lowered yolk cholesterol, serum cholesterol and triglyceride levels                                                                                              0.5--1.5 g/kg          8 weeks                             ([@B136])
                                             Red yeast rice capsule                                                   Japanese quail                                                             Blood and eggs                                              Increased egg production, lowered yolk cholesterol levels                                                                                                                                                                                      0.03--0.12 mg/g        8 weeks                             ([@B127])
  ------------------------------------------ ------------------------------------------------------------------------ -------------------------------------------------------------------------- ----------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------- ----------------------------------- ------------------

Dash (---) denotes no useful information found in the study. HDL-C, high density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; LDL-C, low density lipoprotein cholesterol; SGAs, second-generation antipsychotics; XZK, Xuezhikang; LPL, lipoprotein lipase; LDLR, low density lipoprotein receptor; Hs-CRP, high sensitivity C-reaction protein; PWV, pulse wave velocity; TNF-α, tumor necrosis factor-α; MMP, metalloproteinase; NF-κB, nuclear factor-κB; HCY, homocysteine; ROS, reactive oxygen species; IL, interleukin; PSA, prostate-specific antigen; sAPPR, soluble amyloid precursor protein R-fragment; PPAR, peroxisome-proliferator-activated receptor; ALT, alanine aminotransferase; ACh, acetylcholine; 6-OHDA, 6-hydroxydopamine.
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Hypolipidemic Effect {#s6_1}
--------------------

Hyperlipidemia is the bane of current dietary patterns and rather torpid lifestyles. As a result, the search for supplements that can lower the triglyceride (TG) and cholesterol levels has gained significant momentum. Statins have been used to eliminate vascular occlusions, but with increasing reports of side effects, alternatives are being pursued ([@B125]). In this regard, the hypolipidemic potential of RYR has been consistently proved with reliable experimental results ([@B48]). In dyslipidemia patients, RYR, which was administered as a dietary supplement (4--48 mg/kg), significantly decreased TG, total cholesterol (TC), and low density lipoprotein cholesterol (LDL-C) levels, and increased the high density lipoprotein cholesterol (HDL-C) level ([@B52]; [@B6]; [@B9]). However, further studies that follow patients for longer periods of time are needed to investigate the effects RYR on the risk factors and treatment of various chronic diseases. In animals fed a high-fat diet, the administration of RYR, as a capsule, or RYR aqueous extracts significantly down-regulated TG, TC, and LDL-C levels ([@B149]). These hypolipidemic activities of RYR were mediated at least partially by enhanced acidic sterol excretion and reduced expression of inflammatory transcription factors such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) ([@B110]; [@B35]). However, the mechanisms of action remain to be defined.

The putative hypolipidemic effects of RYR have been mostly ascribed to the rich contents of monacolins and pigments ([@B174]). In a crossover, double-blind, placebo-controlled randomized clinical trial, short-term treatment (4 weeks) with monacolins (10 mg) could significantly reduce TC, LDL-C, and non-HDL levels ([@B28]). However, these results have yet to be confirmed in studies following a larger cohort for a longer period of time. In another study that utilized a high-fat diet rat model, the administration of MK (5--30 mg/kg) decreased serum TC, TG, and LDL-C levels by up-regulating lipoprotein lipase and low density lipoprotein receptor mRNA expression in the liver ([@B19]). The oral administration of RYR yellow, red, and orange pigments also markedly alleviated disturbances in lipid metabolism; ameliorated serum lipid levels; suppressed hepatic lipid accumulation and steatosis; and promoted fecal cholesterol, triacylglycerol, and bile acid excretion. The mechanisms of action involve an up-regulation of the mRNA levels of farnesoid X receptor and peroxisome-proliferator-activated receptor-gamma, the main receptors for the metabolism of cholesterol and homeostasis of bile acids ([@B174]). However, some of these results did not show a dose-effective relationship, and some of these studies lacked positive controls.

RYR is often combined with other products that can effectively reduce lipid levels, such as berberine ([@B116]), policosanols ([@B50]), coenzyme Q~10~ ([@B29]), plant stanols and sterols ([@B44]), olive extracts ([@B142]), and curcumin ([@B31]). Among these, berberine and policosanols have been extensively investigated due to their lipid-lowering properties, in which an increase in LDL receptor half-life and expression and an increase in insulin sensitivity *via* the activation of AMP-activated protein kinase (AMPK) ([@B134]) were observed. *Bifidobacterium longum*, a probiotic strain showing potent hypolipidemic effects, has also been combined with RYR in nutraceutical formulations given that alterations in gut microbiota were found to be involved in the pathogenesis of systemic diseases related to hypercholesterolemia ([@B152]; [@B130]). Additionally, several Chinese medicines have been used with RYR to treat hyperlipidemia, such as *Tao He Cheng Qi Tang* consisting of *Prunus persica* semen, *Cinnamomum cassia* ramulus, *Rheum palmatum* rhizome, natrii sulfas, and *Glycyrrhiza uralensis* rhizome ([@B166]). However, the possible interactions, synergistic effects, and underlying mechanisms of RYR in combination with other ingredients from poly-herbal preparations remain unknown and should be further investigated.

Anti-Atherosclerotic Activity {#s6_2}
-----------------------------

The inhibition of cholesterol synthesis is effective for the primary and secondary prevention of atherosclerotic diseases ([@B94]). Experimental studies in animal and cell models have demonstrated that RYR, as well as Xuezhikang (XZK, its pure extract), has anti-atherosclerotic activity. An eight-week administration of XZK (600--1,200 mg/kg) to C57BL/6 mice was found to significantly and dose-dependently inhibit vulnerable plaque progression, decrease the plaque area, and suppress lesional endoplasmic reticulum stress ([@B132]). In another study involving atherosclerotic rats fed a high-cholesterol diet, the oral administration of RYR at 120 mg/kg significantly reduced the plaque size, stabilized the plaque, protected the endothelium, and decreased the number of lipid droplets and cholesterol calculi, and lowered the levels of high sensitivity C-reaction protein (Hs-CRP), IL-6, and TNF-α, suggesting that the anti-atherosclerotic activity of RYR may be related to inflammatory signaling pathways ([@B161]). The administration of aqueous and ethanol extracts of RYR to homocysteine-treated human aortic smooth muscle cells (HASMCs) (1--160 µg/ml) for 24 h reduced TNF-α-induced metalloproteinase (MMP)-2 and MMP-9 expression. It also reduced nuclear factor-κB (NF-κB) activation and intracellular reactive oxygen species (ROS) formation, supporting the notion that RYR may have a potential application in the treatment of atherosclerosis ([@B101]). Unfortunately, the chemical analyses of XZK and the aqueous and ethanol extracts of RYR were not performed in these studies. Based on the significant decrease in the viability of HASMCs treated with relatively high concentrations of RYR (160 µg/ml), attention should be paid to the possible side-effects in clinical applications.

Anti-Cancer Activity {#s6_3}
--------------------

Cancer, a major disease, is the leading cause of death throughout the world, and developing effective anti-cancer therapies remains a challenge for those in medical research ([@B178]). Previous studies have reported that RYR supplements have anti-cancer activity. The oral administration of RYR (120 mg/kg, qd) to breast cancer patients for 12 weeks significantly decreased serum tumor biomarker (CA125, CA153) levels and improved their life quality and immune function after chemotherapy and resection surgery ([@B173]). Although this study showed that RYR possesses anti-cancer activity, only a single dose was used, thereby limiting information on the dose-dependent effect. In SCID tumor mice induced by human prostate cancer cells, the administration of powdered RYR significantly reduced the oral tumor volume and decreased the serum prostate-specific antigen level, as well as the gene expression of enzymes involved in androgen synthesis (HSD3B2, AKR1C3, and SRD5A1) ([@B59]). Thus, clinical studies of RYR use for the prevention of prostate cancer in men undergoing active surveillance of the disease should be considered.

Studies have reported that polysaccharides, monacolins, and pigments from RYR are responsible for the anti-cancer activity of RYR. The administration of RYR polysaccharides (at a very high dose of 800 mg/kg) to replanted S~180~ tumor mice for 2 weeks remarkably inhibited tumor growth and improved body weight ([@B36]). However, this trial lacked a positive control as well as an evaluation of serum biochemical indicators of the tumor. In K-562, SK-OV-3, and SNU-1 cells, the administration of rubropunctatin, a red pigment, and RYR-derived monacolin L (1.25--40 µg/ml) for 48 h exhibited very strong inhibitory effects against cancer cell proliferation, and the effect of rubropunctatin was comparable with that of anti-cancer drugs *cis*-platinum, taxol, and 10-hydroxy-camptothecin in their IC~50~ values. In this study, the authors demonstrated that RYR at least partially exerted its anti-cancer effects through telomerase-mediated inhibition of rubropunctatin and monacolin L-induced apoptosis ([@B163]). However, both studies failed to discuss the effectiveness of RYR-derived monacolin and pigments using animal models, and more in-depth studies should be carried out to further develop these compounds into anti-cancer drugs.

Neurocytoprotective Activity {#s6_4}
----------------------------

RYR extracts have also been shown to possess neurocytoprotective activity. In rats treated with amyloid β (Aβ), an amino acid associated with Alzheimer's disease, the oral administration of RYR (151--755 mg/kg) for 4 weeks could markedly reverse the memory deficits in the water maze and passive avoidance tasks, as well as prevent Aβ40 infusion and damage in the hippocampus and cortex, which are known involve in the increase of thiobarbituric acid reactive substances and ROS. Using human neuroblastoma IMR32 cells exposed to a high concentration of cholesterol, the authors also reported that RYR down-regulated Aβ40 formation and deposition by suppressing cholesterol-induced β-secretase activity and apolipoprotein E expression. RYR also mediated the proteolysis of amyloid precursor protein (APP) into a soluble APP α-fragment with neuroprotective activity in the hippocampus ([@B87]). However, further studies are needed to confirm the neurocytoprotective effect using low doses of RYR suitable for human administration. Lovastatin derivatives are also responsible for the neurocytoprotective effect of RYR. The administration of one lovastatin-derived compound, designated **3f** (12.5--100 µmol/L), for 24 h significantly reduced 6-hydroxydopamine (6-OHDA)-induced apoptosis in PC12 cells, reduced caspase-3, -8, and -9 activities, and lowered intracellular calcium concentrations elevated by 6-OHDA in a concentration-dependent manner, without inhibiting the production of ROS ([@B102]). Studies on the mechanism of action of compound **3f** are being conducted.

Hepatoprotective Effect {#s6_5}
-----------------------

RYR extracts exhibit a strong hepatoprotective effect both in alcoholic fatty liver and non-alcoholic fatty liver disease (NAFLD) mice models. In chronic alcohol-induced mice, the oral administration of powdered RYR (307.5--1,537.5 mg/kg) for 5 weeks significantly attenuated the increased levels of serum transaminases (aspartate aminotransferase and alanine aminotransferase), hepatic TGs, and TC. Furthermore, RYR elevated the hepatic antioxidant activity that reduced hepatic cell damage (steatosis) and decreased tissue inflammatory cytokine levels ([@B20]). These findings suggested that RYR may represent a novel, protective strategy against alcoholic liver disease by attenuating oxidative stress, inflammatory responses, and steatosis. However, the authors of this study did not perform comparisons using a positive control. The administration of RYR extracts (XZK at 300 mg/kg) to NAFLD mice for 6 weeks significantly ameliorated dyslipidemia and fat accumulation in the liver; improved insulin resistance; ameliorated oxidative stress; lessened hepatic steatosis, necro-inflammation, and collagen deposition; and reversed abnormalities in the aminotransferase level. The mechanism of action of RYR likely involves inhibition of the hepatic expression of TNF-α ([@B56]). These results suggested that RYR may have a potential clinical application in the treatment of NAFLD. In this study, however, the optimal dose, constituents, and side effects of RYR were not assessed.

Anti-Osteoporotic Activity {#s6_6}
--------------------------

Osteoporosis is a common health problem characterized by low bone mass and structural deterioration of the bone, resulting in an increased susceptibility to fractures ([@B172]). Several studies have reported the protective role of RYR in osteoporosis. In rats with ovariectomy-induced bone loss and osteoblast cells, the administration of ethanol extracts from RYR (at a very high dose of 1.56--6.24 g/kg) for 20 weeks significantly increased the bone mineral density and decreased the levels of bone turnover markers *in vivo*, including osteocalcin and tartrate-resistant acid phosphatase. Moreover, its administration improved the viability of osteoblasts and enhanced the mRNA and protein expression of bone morphogenetic protein (Bmp) 2 and Bmp4, suggesting that RYR may be useful in preventing and treating osteoporosis ([@B146]). However, future studies should confirm this anti-osteoporotic effect under clinical conditions with low doses of RYR that are suitable for human administration. In rabbits with bone defects and UMR 106 cells, the administration of RYR extracts significantly promoted new bone formation *in vivo*, enhanced bone optical density, and increased alkaline phosphatase activity *in vitro*, suggesting that RYR is a natural product that can potentially treat bone defects and osteoporosis ([@B157]). However, additional evidence from randomized controlled trials is required to identify other regulatory mechanisms that may be responsible for the anti-osteoporotic effects. The bioactive constituents of these extracts also remain unknown.

Anti-Fatigue Activity {#s6_7}
---------------------

RYR extracts exhibit strong anti-fatigue capability. The oral administration of RYR (24 mg/kg) to dyslipidemia patients for 4 weeks was found to significantly reduce muscle fatigue and preserve physical activity ([@B165]). Nevertheless, only a single dose of RYR was used in this study. In a Wistar rat model, the administration of powdered RYR (at a very high dose of 1--5 g/kg) for 4 weeks significantly extended the swimming time for the rats, effectively delayed the lowering of the glucose level in the blood, prevented the increase in lactate and blood urea nitrogen concentrations, and decreased the contribution of exercise-induced oxidative stress, suggesting that RYR has anti-fatigue activity and may potentially be a useful pharmacological agent ([@B143]). However, the main shortcomings of this study were that the dose of RYR was too high and no mechanism of action was provided. RYR extracts are abundant monacolins and pigments. The administration of MK (10--90 mg/kg) or ethanol-soluble red pigments (50--200 mg/kg) to mice for 30 days significantly improved the hepatic glycogen level, decreased the serum urea nitrogen level, and increased the swimming time in an endurance test, indicating that MK and red pigments are responsible for the anti-fatigue activity of RYR ([@B19]). However, future studies are needed to identify the mechanism of action of these constituents.

Anti-Diabetic Activity {#s6_8}
----------------------

Diabetes is assuming epidemic proportions across the world ([@B82]). The best approach to control hyperglycemia and mitigate diabetes is dietary intervention, rather than a reliance on drugs ([@B125]). In this regard, the possible role of RYR was investigated. The administration of RYR (50--350 mg/kg) to streptozotocin-induced diabetic rats for 2 weeks markedly decreased the plasma glucose level, reversed hyperphagia, and decreased the mRNA level of phosphoenolpyruvate carboxykinase in the liver in a dose-dependent manner, indicating that RYR decreased hepatic gluconeogenesis and lowered the plasma glucose level in diabetic rats ([@B12]). A similar study has reported that RYR could promote the release of acetylcholine from nerve terminals, which in turn stimulated muscarinic M3 receptors in pancreatic cells and augmented insulin release in order to lower the plasma glucose level ([@B13]). In another study, the administration of RYR (300 mg/kg) to diabetic mice for 8 weeks significantly decreased the blood glucose level by improving glucose tolerance and insulin secretion, protected islets from hyperglycemic injury, and inhibited the expression of key factors in oxidative stress, including 8-OHdG, 4-HNE, and gp91phox, indicating that the effects of RYR on oxidative stress may at least partly account for the improved insulin secretion of pancreatic islets in diabetes ([@B145]). However, this evidence is still tenuous; no detailed clinical trials involving RYR supplementation have been performed, and no chemical constituents of RYR responsible for the anti-diabetic activity have been presented. Furthermore, several studies also failed to include positive controls and dose-dependent effect analyses.

Anti-Obesity Activity {#s6_9}
---------------------

Obesity is defined as an excess of white adipose tissue, which is associated with a higher risk of developing diabetes and cardiovascular disease ([@B113]). RYR has been shown to possess anti-obesity activity. In mice fed a high-fat diet, the administration of RYR (at a very high dose of 4--20 g/kg) significantly lowered weight gain and fat pad mass, which was accompanied by smaller fat cells. The anti-obesity effects of RYR were mainly derived from the lipolytic activity and mild anti-appetite potency of RYR. In 3T3-L1 cells, the investigators demonstrated that RYR extracts suppressed the proliferation and differentiation of preadipocytes, which may have inhibited new adipocyte formation or hyperplasia in adipose tissue ([@B15]). The main shortcoming in this study was the very high dose of RYR, which will restrict the clinical application of RYR in the treatment of obesity.

Anti-Inflammatory Activity {#s6_10}
--------------------------

Inflammation signifies an agitated metabolic and immunological system ([@B122]), and anti-inflammatory drugs that can restore the homeostasis of a perturbed system are in great demand. Various anti-inflammatory drugs exist, although many associate with adverse effects ([@B125]). RYR has been reported to possess an inflammation-quenching effect. In RAW264.7 cells induced by lipopolysaccharide, the administration of azaphilonoid derivatives isolated from RYR (5--20 µg/ml), including monapurfluores A and B, monascopyridines C and D, and monasfluores A and B, significantly inhibited the release of the inflammatory mediator nitric oxide (NO) from macrophages ([@B63]). NO has been reported to be a signaling agent for various inflammatory diseases; therefore, its suppression is likely to ameliorate irritation ([@B125]). However, this study failed to include a positive control, and other inflammatory indicators, such as IL-1β, TNF-α, and IL-6, should be studied in the future. In mice fed a high-cholesterol diet, the administration of XZK (300 mg/kg) for 6 weeks significantly reduced the levels of the inflammatory transcription factors TNF-α and IL-6, and attenuated renal injury by managing the abnormal lipid levels and the consequent stress ([@B35]). This study also lacked a positive control, and the effects of the various doses were not assessed.

Anti-Hypertensive Activity {#s6_11}
--------------------------

Hypertension, commonly recognized as a silent killer, is the most common cardiovascular disease and a major risk factor for atherosclerosis, metabolic syndrome, renal dysfunction, myocardial infarction, heart attack, and stroke, which are the most prevalent causes of death in industrialized countries ([@B156]; [@B144]). As many drugs have side effects, healthy diets are expected to prevent or alleviate the complications. The potential of RYR, in combination with other bioactive components, to manage the problem is discussed below. In grade 1 essential hypertension patients, the administration of a nutraceutical formulation containing RYR, folic acid, coenzyme Q~10~, *Orthosiphon stamineus* (a tropical herb from the Lamiaceae family), policosanol, and berberine significantly reduced the mean 24-h systolic and diastolic blood pressure levels ([@B141]). However, the ratios between RYR and the other constituents are not optimized based on the anti-hypertensive activity. In spontaneously hypertensive rats, the intravenous bolus administration of RYR ethanol extracts (10--50 mg/kg) elicited biphasic and potent hypotensive and cardiac inhibitory effects, as well as a significant decrease in sympathetic vasomotor activity ([@B144]). Further studies are needed to identify the chemical constituents in RYR ethanol extracts responsible for the anti-hypertensive effects. Meta-analysis of the existing literature showed that RYR, together with conventional therapy and statins, can lower the systolic blood pressure, without any significant adverse side effects ([@B125]; [@B162]). Taken collectively, the results are encouraging but limited. Although meaningful reductions in blood pressure have been observed, evidence for the use RYR in the treatment of hypertension is weak based on the available data. Thus, more rigorous, high-quality trials are required to provide stronger evidence.

Other Activities {#s6_12}
----------------

Polysaccharides from RYR have been shown to possess immunomodulatory activity. In a mice model, the administration of RYR-derived polysaccharides (50--300 mg/kg) significantly improved the phagocytic activity of abdominal cavity macrophages, prompted the formation of the peripheral blood E-rose loop, increased the transformation rate of lymphocytes, and enhanced nonspecific immunity ([@B168]). However, this study failed to include a positive control, and the relationship between polysaccharide structure and immunomodulatory activity should be further investigated. In laying hens, the administration of RYR significantly increased the laying rate, Haugh units, and albumen height, as well as decreased the yolk cholesterol content, suggesting that RYR plays important roles in improving the production and quality of eggs ([@B136]). Further studies are required to determine the level of citrinin, a nephrotoxin in RYR, in the serum and eggs of hens in order to meet a lower citrinin level with regard to RYR production.

Methane (CH~4~), a greenhouse gas that is 25 times more effective than carbon dioxide in global warming, is emitted during enteric fermentation in ruminants, accounting for approximately 10% of the total anthropogenic CH~4~ ([@B55]; [@B62]). In a castrated Boer crossbred goat model, the administration of RYR significantly reduced enteric CH~4~ emissions, serum lipid levels, and the growth of several archaeal species (e.g. *Methanobrevibacter*) in the rumen. Therefore, as a natural fermentation product, RYR can reduce enteric methane emissions in goats ([@B147]). However, caution should be taken when considering the digestibility of protein and organic matter, and further studies are needed to evaluate its effects in different animals with various diets as well as its effects on animal health and food safety.

Pharmacokinetic Studies {#s7}
=======================

MK (also known as lovastatin), categorized as a class II compound according to the Biopharmaceutics Classification System (BCS), is mainly responsible for the blood cholesterol lowering effect of RYR ([@B158]). MK exhibits poor oral bioavailability (\<5%) because of its low solubility (1.3 µg/mL in water), extensive metabolism in the gut and liver, and transmembrane efflux *via* the drug transporter P-glycoprotein ([@B131]; [@B14]). Its bioavailability can be improved by increasing the dissolution rate and/or decreasing pre-systemic clearance ([@B119]; [@B159]). In Caco-2 cells, extracts of RYR (LipoCol Forte, XZK, and Cholestin) were more effective in inhibiting the activities of CYP450 enzymes and P-glycoprotein, and showed higher lovastatin absorption and dissolution rates than that of lovastatin alone ([@B16]; [@B18]). Moreover, in human studies, the authors demonstrated that volunteers receiving LipoCol Forte capsules or powder exhibited higher area under the plasma concentration-time curve and C~max~ (maximum plasma concentration) values for both lovastatin and its active metabolite, lovastatin acid, and lower T~max~ (time to reach the peak concentration) values than those receiving lovastatin tablets, suggesting that the oral bioavailability of lovastatin is significantly improved when combined with RYR as a result of the higher dissolution rate ([@B18]). In this regard, the increased dissolution rate seen with RYR products might enable lovastatin (a BCS class II drug) to function as a BCS class I drug. Additionally, Leone and colleagues ([@B92]) prepared a new formulation that combined 60% gelatin with 40% alginate. They observed a delayed release of lovastatin from RYR, a prolonged inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and decreased cholesterol synthesis. However, further studies are needed to explore the underlying mechanism of actions, as well as the pharmacokinetics of the other bioactive compounds present in RYR, including monacolins and pigments such as rubropunctamine, monascorubramine, and ankaflavin.

Quality Control {#s8}
===============

To assess and control the quality of RYR, the Chinese Pharmacopoeia suggests using morphology, ultraviolet-visible spectrophotometry, thin-layer chromatography, and high-performance liquid chromatography (HPLC). MK can be used as a marker of quality in the official monograph of the RYR as well as in the label claim of several commercial RYR-related products. The MK content of RYR should be more than 0.22% by HPLC ([@B25]). However, the European Commission has not legislated on the limits for RYR supplements and there is no standardization in European countries, while the Food and Drug Administration (FDA) has stated in 2007 that RYR products containing MK are identical to a drug, and therefore, subject to regulation ([@B42]). With regard to therapeutic efficacy, a 2011 European Food Safety Authority (EFSA) report confirmed that the daily intake of 10 mg of MK was beneficial in maintaining normal cholesterol levels ([@B39]). However, manufactures of RYR products rarely disclose the levels of MK and the active ingredients are not standardized.

Various methods are available for the determination of the MK level in RYR products, including HPLC ([@B139]), ultra-high-performance liquid chromatographic with diode array detection and/or with mass spectrometry (UHPLC--DAD--QToF-MS) ([@B3]), matrix effect-free MISPE-UHPLC-MS/MS ([@B137]), LC-DAD/FLD (fluorescence detection)-MS^n^ ([@B117]), UHPLC hyphenated with triple quadrupole tandem MS (UHPLC--QQQ-MS) ([@B177]), flow injection FI-MS/MS ([@B133]), square-wave voltammetry ([@B121]), and contact angle, atomic force microscopy with Fourier transform infrared spectroscopy ([@B41]). However, the use of only one quantitative marker may be insufficient to properly assess the quality of RYR extracts. There is evidence to indicate that the pigments found in RYR have hypolipidemic ([@B174]), anti-cancer ([@B163]), anti-fatigue ([@B19]), and anti-inflammatory ([@B63]) activities, and therefore, the presence of pigments may be a critical indicator of extract quality. Although several pigments, such as rubropunctatin, monascorubrin, monascin, monasfluore A, and monasfluore B, have been identified in RYR by liquid chromatography--mass spectrometry (LC-MS) ([@B74]), HPLC-FLD ([@B67]), and HPLC-UV ([@B68]), more rapid, sensitive, and selective technologies should be developed for the detection of pigments.

In RYR extracts, the content of active ingredients, which includes MK, pigments, phenolic compounds, and flavonoids, varies in quality with the fermentation process, extraction procedures used, strain of *M. purpureus*, and storage conditions. The MK concentration in RYR can be increased by the mixed-culture fermentation of rice with two different Monascus species (*M. purpureus* and *M. ruber*), with the optimized fermentation process parameters including a pH of 6.03 at a temperature of 29.46°C for 13.89 days. This process predicts 2.83 mg/g and yields 2.80 mg/g of MK/gram of fermented rice with 98.93% accuracy ([@B124]). Moreover, the supplementation of the fermentation substrate with nitrogen sources influences the pigment production efficiency of RYR. For instance, the addition of orange peels and sunflower meal to solid-state fermentation (SSF) cultures of *M. purpureus* can enhance pigment production in RYR, yielding 9 absorbance units (AU)/per g of dry fermented substrate (gdfs) ([@B76]). Babitha and colleagues ([@B5]) reported that the addition of monosodium glutamate to jackfruit seed SSF of *M. purpureus* improved the production of red (30.8 AU/gdfs) and yellow (25.5 AU/gdfs) pigments, followed by the addition of soybean meal, peptone, and chitin powder. In addition, a combination of light and bacteria can be used to enhance secondary metabolite production during RYR fermentation. The fermentation of RYR with *Bacillus subtilis*, a rod-shaped, Gram-positive endospore-forming bacterium, under blue light-emitting diodes enhanced the production of phenolic compounds (68.4 ± 1 mg GAE/g DW) and flavonoids (51.7 ± 1 mg QE/g DW) compared to white light and darkness ([@B40]). Further studies should focus on the molecular mechanisms and optimization of conditions for the commercial-scale production of these secondary metabolites. Under optimal extraction conditions with 45% ethanol, 1.5% phosphate, and an extraction time of 70 min, 91.6% of citrinin was removed and 79.5% of MK was retained in the final RYR extract ([@B84]). *M. purpureus* strains are commonly used to enhance the production of MK and pigments in RYR. Using rigorous physicochemical mutagenesis technologies involving ultraviolet-lithium chloride, microwave heating, and genome shuffling mutations, two mutant *M. purpureus* strains, strain 183-3 with a highly stable capacity to produce pigment and strain R"-30 with a highly stable capacity to produce MK, were obtained ([@B164]; [@B98]). In addition, Li et al. reported that the MK content in RYR significantly decreased under conditions of high humidity, high temperature (75% RH, 60°C), and sunlight, indicating that MK in RYR is light- and heat-sensitive, and RYR should be stored in the cool and dark place ([@B93]).

The area in which RYR is produced also influences its quality. RYR is now produced in more than 120 cities in 15 countries in Asia, Europe, and North America, such as China, Japan, the United States, Germany, Italy, Thailand, India, Korea, and Belgium. The general geographical distribution of RYR is shown in [**Figure S2**](#SM2){ref-type="supplementary-material"}. In studies that used UHPLC--DAD--QToF-MS to determine the MK content in 26 brands of RYR from four large retail chains in the United States (i.e. GNC, Walgreens, Walmart, and Whole Foods), it was reported that the MK content was highly variable, ranging more than 60-fold from 0.09 to 5.48 mg per 1,200 mg ([@B30]). In another study that involved LC-PDA-MS, Huang and colleagues found that RYR from cities in Fujian Province, especially *Gutian*, *Nanping*, and *Pinnan*, possessed a higher MK content compared to six other habitats in China ([@B64]). These results indicate that the MK content in RYR extracts significantly differs between samples from different habitats. Thus, the MK content should be compared across RYR products, uniform legislation should be proposed, and strict quality control of RYR extracts should be implemented.

Citrinin is a polyketide secondary metabolite found in food and feed that is produced by several fungi, including *M. purpureus* ([@B7]; [@B77]). It is a mycotoxin known to cause kidney damage as well as disrupt metabolic processes in the liver ([@B117]). Citrinin, as a component, has been involved in several controversies related to the quality and safety of RYR products, because up to 80% of RYR products may contain this mycotoxin ([@B53]). The EFSA has set a level of no concern for citrinin-caused nephrotoxicity at 0.2 µg/kg body weight per day, but it has acknowledged the need for more reliable data on the citrinin level in food and feed before it can undertake exposure studies and risk assessment ([@B112]). Different analytical methods have been developed for the quantification of citrinin in a variety of samples in the last few years, including LC-FDA ([@B112]), UHPLC-MS/MS ([@B77]), UHPLC--DAD--QToF-MS ([@B3]), LC-DAD/FLD-MS^n^ ([@B117]), microsphere-based flow cytometric immunoassays (MFCI) ([@B97]), and a multi-commutated fluorometric optosensor technology ([@B73]). The maximum allowed level of citrinin as a contaminant in RYR is 200 ppb in Japan, but the European Union has recommended a limit of 100 ppb ([@B117]; [@B120]). However, many commercial RYR products do not meet the criteria, and the highest citrinin concentration detected by HPLC was 140 mg/kg ([@B70]). More in-depth studies are necessary to arrive at more accurate conclusions and to extrapolate data for risk assessment with respect to the prevalence of citrinin in our food chain and its potential impact on human health.

Safety and Adverse Effects {#s9}
==========================

According to the currently available results of *in vitro* and *in vivo* studies, RYR does not seem to be no mutagenic or toxic. In an albino rat model, the administration of acute doses of RYR at 0.5--5.0 g/kg body weight did not cause toxicity or mortality. Similarly, the administration of RYR at a level of 2.0--12.0% (w/w) for 14 weeks did not produce any significant changes in the food intake or body weight of the treated rats compared to control rats ([@B80]). In an Ames test, the equivalent of up to 1 mg of ethanol extract from RYR per plate exhibited no genotoxicity toward *Salmonella typhimurium* strains TA 98, TA 100, and TA 102. Moreover, it has been reported that high levels of RYR exhibited no toxicity, following subchronic administration at levels up to 1,000 mg/kg of body weight for 28 and 90 consecutive days in the rats ([@B167]).

However, RYR does have adverse effects because MK and citrinin associate with an increased risk of myopathy ([@B83]; [@B128]; [@B37]), symptomatic hepatitis ([@B129]), peripheral neuropathy ([@B81]), erectile dysfunction ([@B105]), and anaphylactic reactions ([@B54]). Among these, the prevalence rates of myopathy and hepatitis are the highest. Using Italy's WHO-UMC system, CIOMS/RUCAM score, and WHO-Vigibase, 52 out of 1,261 studies reported 55 adverse reactions to RYR dietary supplements from April 2002 to September 2015, and myopathy and hepatitis accounted for 52.73% of the total adverse reactions ([@B115]). Although RYR supplementation appears promising for patients with hypercholesterolemia or hyperlipidemia or those at high risk for cardiovascular events, there is insufficient regulation of RYR-containing supplements in China, the United States, and European countries. Until there is a standardized system in place for product formulation and manufacturing, and the amount of MK in a given RYR supplement is clearly stated, the effectiveness and safety of these products will remain in question ([@B38]; [@B126]). Thus, real-world vigilance should be used, and it should include consumers, clinicians, and policymakers to promote the proper use of RYR. Furthermore, randomized controlled trials should be carried out to test the safety and efficacy of each RYR preparation.

The safety profile of RYR supplements is highly similar to that of statins ([@B115]). Some statins, including lovastatin (MK in RYR), are metabolized by the cytochrome P450 enzyme CYP3A4 and it is known that coadministration of drugs that inhibit CYP3A4 can increase the plasma half-lives of these statins and the risk of myotoxicity ([@B114]). CYP3A4 inhibitors reported to interact with statins and to cause rhabdomyolysis include clarithromycin ([@B49]), verapamil ([@B27]), cyclosporine ([@B123]), diltiazem ([@B4]), itraconazole ([@B118]), and azithromycin ([@B49]). Statin-induced rhabdomyolysis may result from increased exposure to the drug, plausible mechanisms for the interaction include increased absorption of lovastatin by competition at gut P-glycoprotein or decreased excretion of statin due to competition for renal tubular secretion or interaction at hepatic CYP3A4 sites ([@B34]). Co-administration of a statin and a fibrate drug also increases the rhabdomyolysis risk, and gemfibrozil in particular should be avoided in patients receiving lovastatin ([@B45]). Therefore, the healthcare providers need to heighten their awareness and screening for potential drug-drug interaction in patients consuming RYR products, and consider early monitoring of liver function and signs of muscle injury. In parallel, consumers should be informed that MK contained in RYR is identical to lovastatin, and need to be discouraged from using RYR preparations as self-medication, particularly if they have experienced previous adverse reactions to statins.

Conclusions and Future Perspectives {#s10}
===================================

RYR is widely used in prescriptions, as well as an alternative medicine and a food supplement, in Asia, the United States, and European countries. This review summarized the current information on the traditional uses, chemistry, pharmacology, pharmacokinetics, quality control, and toxicity of RYR. In classical Chinese herbal textbooks and the Chinese Pharmacopoeia, RYR is commonly used for resolving turbidity, invigorating blood circulation, and resolving blood stasis. Pharmacological studies have revealed that RYR possesses many biological properties with hypolipidemic, anti-atherosclerotic, anti-cancer, neurocytoprotective, hepatoprotective, anti-osteoporotic, anti-fatigue, anti-diabetic, anti-obesity, immunomodulatory, anti-inflammatory, anti-hypertensive, and anti-microbial activities. The results of these pharmacological investigations support the traditional use of RYR. Furthermore, more than 101 compounds have been isolated from RYR. Among these, monacolins and pigments are the most abundant and the major bioactive constituents in RYR.

Outstanding progress has been made in the chemistry and pharmacology of RYR. However, several gaps in knowledge will require additional studies. Firstly, the systematic data on the toxicology and drug interactions of RYR extracts are limited, and there are only a few studies documenting the toxic effects of RYR. Presently, the evidence is insufficient for RYR to be interpreted as toxic. Thus, a comprehensive toxicological study of both the bioactive extracts and isolated constituents from RYR is urgently needed. Furthermore, due to its potential *in vitro* and *in vivo* toxic effects, the clinical application of RYR should be restricted until more definitive studies demonstrate its safety, quality, and efficacy. Secondly, although monacolins in RYR have been found to possess pharmacological activities that are similar to those in pigments, such as hypolipidemic activity, the mechanisms underlying the absorption, distribution, metabolism, and excretion, as well as the synergistic or antagonistic effects between the two constituents, are unknown; thus, they should be further studied. Moreover, other bioactive constituents of RYR, such as organic acids, sterols, decalin derivatives, and flavonoids, should also be examined for their potential use in the development of drugs and as a food supplement. Thirdly, well-designed pharmacodynamic and pharmacological studies should be designed, and comprehensive investigations should be conducted to identify the relevant compounds responsible for the pharmacological effects and the potential mechanisms. Fourthly, although the pharmacological properties support the traditional uses of RYR in the treatment of blood circulation stasis, bone defects, and limb weakness, additional pharmacological studies are needed to address its use in the remediation of indigestion and diarrhea. Finally, the possible interactions, safety profile, synergistic or antagonistic effects, and underlying mechanisms between the bioactive compounds present in RYR and other combined used products remain unknown and should be further studied.

In conclusion, future studies should focus on the absorption, distribution, metabolism, and excretion of monacolins and their interactions with pigments, which would promote our understanding of the underlying mechanisms of the various biological activities of RYR. Further research should also consider the pharmacological activities that were overlooked with regard to the traditional uses of RYR, especially in the treatment of gastrointestinal diseases, such as indigestion and diarrhea. Finally, more efforts are needed in order to gain new insights into the toxicological effects of the main active compounds and the quality control of RYR based on its diverse chemical constituents.
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###### 

Click here for additional data file.

###### 

The general geographical distribution of RYR.

###### 

Click here for additional data file.

###### 

Examples of traditional Chinese medicine prescriptions containing red yeast rice.

###### 

Click here for additional data file.

[^1]: Edited by: Lyndy Joy McGaw, University of Pretoria, South Africa

[^2]: Reviewed by: Ligia Salgueiro, University of Coimbra, Portugal; Shuai Ji, Xuzhou Medical University, China

[^3]: This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology

[^4]: †These authors share first authorship
